Abstract:The activity of nucleoside and nucleotide analogs as antiviral agents requires phosphorylation by endogenous enzymes. Phosphate-substituted analogs have low bioavailability due to the presence of ionizable negatively-charged groups. To circumvent these limitations, several prodrug approaches have been proposed. Herein, we hypothesized that the conjugation or combination of the lipophilic amide bond with nucleotide-based tenofovir (TFV) (1) could improve the anti-HIV activity. During the current study, the hydroxyl group of phosphonates in TFV was conjugated with the amino group of L-alanine, L-leucine, L-valine, and glycine amino acids and other long fatty ester hydrocarbon chains to synthesize 43 derivatives. Several classes of derivatives were synthesized. The synthesized compounds were characterized by 1H NMR, IR, UV, and mass spectrometry. In addition, several of the synthesized compounds were evaluated as racemic mixtures for anti-HIV activity in vitro in a single round infection assay using TZM-bl cells at 100 ng/mL. TFV (1) was used as a positive control and inhibited HIV infection by 35%. Among all the evaluated compounds, the disubstituted heptanolyl ester alanine phosphonamidate with naphthol oleate (69), pentanolyl ester alanine phosphonamidate with phenol oleate (62), and butanolyl ester alanine phosphonamidate with naphthol oleate (87) ester conjugates of TFV were more potent than parent drug TFV with 79.0%, 76.5%, 71.5% inhibition, respectively, at 100 ng/mL. Furthermore, two fatty acyl amide conjugates of tenofovir alafenamide (TAF) were synthesized and evaluated for comparative studies with TAF and TFV conjugates. Tetradecanoyl TAF conjugate 95 inhibited HIV infection by 99.6% at 100 ng/mL and showed comparable activity to TAF (97-99% inhibition) at 10-100 ng/mL but was more potent than TAF when compared at molar concentration.

Synthesis and Metabolism Studies in vitro of d4T-5'-H-phosphonate Prodrugs

Synthesis and spectroscopic analysis of 2′,3′-didehydro- 2′,3′-dideoxythymidine (d4T) 5′-thiophosphoramidates

Comparison of the Phosphorylation of 4′-Ethynyl 2′,3′-Dihydro-3′-deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs

Synthesis, In Vitro Biological Stability, and Anti-HIV Activity of 5-Halo (or Methoxy)-6-Alkoxy (Azido or Hydroxy)-5,6-Dihydro-2′,3′-Didehydro-3′-Deoxythymidine Diastereomers as Potential Prodrugs of 2′,3′-Didehydro-3′-deoxythymidine (D4T)

Synthesis of Novel 5′-Hydrogenphosphonothioate Derivatives of AZT, d4T and ddI

Synthesis of AZT/d4T Boranophosphates as Anti-HIV Prodrug Candidates

Membrane Permeable, Bioreversibly Modified Prodrugs of Nucleoside Diphosphate-γ-Phosphonates

New and Efficient Approach to Aryl Phosphoramidate Derivatives of AZT/d4T as Anti-HIV Prodrugs

Synthesis and Anti‐HIV Activity of a Series of 6‐modified 2′,3′‐dideoxyguanosine and 2′,3′‐didehydro‐2′,3′‐dideoxyguanosine Analogs

Antiviral Activity of Lipophilic Nucleoside Tetraphosphate Compounds

One-Pot Synthesis of Aryl Phosphoramidate Derivatives of Azt/D4t As Anti-Hiv Prodrugs

Tumor suppressive effect of lysyl oxidase proenzyme.

Novel Use of a Guanosine Prodrug Approach to Convert 2',3'-Didehydro-2',3'-dideoxyguanosine into a Viable Antiviral Agent.

Design, synthesis and biological evaluation of aryloxy thiophosphoramidate triesters of anticancer nucleoside analogues

CosmeceutiQoL: A tool for assessing dermo-cosmetic products’ impact on quality of life

Synthesis, in Vitro Anticancer Evaluation, and Interference with Cell Cycle Progression of N-Phosphoamino Acid Esters of Zidovudine and Stavudine

Synthesis and Antiviral Evaluation of 3'- C -Hydroxymethyl-3'- O -Phosphonomethyl-β-D-5'-deoxyxylose Nucleosides

Synthesis and Antiviral Activities of Isonucleosides and Their Monophosphates

Synthesis and Evaluation of Anti-HIV Activity of Mono- and Di-Substituted Phosphonamidate Conjugates of Tenofovir

Synthesis and in vitro antitumour activity of 4(R)-methyl-3-O-phosphonomethyl-α-l-threose nucleosides

Mechanism of Anti-Human Immunodeficiency Virus Activity of Β- D -6-Cyclopropylamino-2′,3′-didehydro-2′,3′-dideoxyguanosine